Skip to main content
Toggle navigation
Search
Home
Icon Legend
Food/Drinks Available
CE's Available
Reception
Pre-registration Required
Livestreaming
Recorded Session
GI/NUTRITION
Home
GI/NUTRITION
GI/NUTRITION
Type here to filter the list
(188) Body Mass Index Versus Mid-upper Arm Circumference: Can We Replace The Gold Standard?
Favorite
(189) Impact of elexacaftor/tezacaftor/ivacaftor on Body Composition in a Small Cohort of Youth with Cystic Fibrosis
Favorite
(190) Hyperosmolar salt concentrations slow digestion of milk and meconium by pancreatic enzymes.
Favorite
(191) CFTR Potentiator (Ivacaftor) has Minimal Effects on Gut Microbiome Composition in People with Cystic Fibrosis and Gating Mutations
Favorite
(192) Gastrointestinal symptoms in a CFTR modulator era – an international survey
Favorite
(193) Cystic fibrosis-related liver disease is associated with an increased risk of mortality and a higher disease burden in pediatric patients with cystic fibrosis
Favorite
(194) Building an in vitro model to investigate microbial dynamics in the CF gut
Favorite
(195) The impact of elexacaftor/tezacaftor/ivacaftor (Trikafta) on serum markers of fat-soluble vitamin levels in people with cystic fibrosis
Favorite
(196) Liver function test abnormalities in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Favorite
(197) Rare prevalence of colonic sessile serrated lesions in cystic fibrosis patients
Favorite
(198) Weight and Body Composition in School-Age Children with CF and Extended Modulator Therapy
Favorite
(199) ÂPersistent immaturity of the developing gut microbiome in infants with cystic fibrosis
Favorite
(200) Efficacy of cyproheptadine for appetite stimulation in pediatric cystic fibrosis patients
Favorite
(201) Caregiver perceptions of a lifestyle education tool and subsequent behavior changes with Elexacaftor-Tezacaftor-Ivacaftor initiation
Favorite
(202) Clinical Characteristics of Children with Cystic Fibrosis Who Receive Gastrostomy Tubes
Favorite
(203) Re-Evaluating the Expression Profile of SLC26A3 (DRA) Chloride/Bicarbonate Exchanger in the Small Intestine using Human Models: Implications for Cystic Fibrosis
Favorite
(204) Should DEXA form part of routine nutrition assessments in children with CF?
Favorite
(205) Do we need a colorectal cancer screening programme for patients with cystic fibrosis?
Favorite
(206) Investigating Colonic pH in Cystic Fibrosis: Wireless Motility Capsule to Single-Cell Sequencing
Favorite
(207) Repeat Fecal Elastase Testing in Pediatric Patients on CFTR Modulator Therapy
Favorite
(208) Fat soluble vitamin level trends post-elexacaftor/tezacaftor/ivacaftor therapy
Favorite
(209) Metabolic changes post elexacaftor/tezacaftor/ivacaftor in a Northern Ireland Population with Cystic Fibrosis
Favorite
(210) Mid-Upper Arm Circumference in Children with CF: Changes Seen with Highly Effective Modulator Therapy
Favorite
(211) Increasing BMI % In Cystic Fibrosis (CF) Clinic Using Novel Algorithm
Favorite
(212) BMI changes over time and post CFTR modulator in a population with cystic fibrosis
Favorite
(213) Fecal Microbiota with 1 Month of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients with Cystic Fibrosis: Preliminary Findings from PROMISE Pediatrics Study
Favorite
(214) Combination vitamin therapy is non-inferior to individual supplementation therapy in children with cystic fibrosis
Favorite
(215) Genetic modifiers of nutritional status in CF are both unique to CF and shared with the general population
Favorite
(216) Approved drug lubiprostone is not a selective Clc-2 activator and its prosecretory effect primarily depends on CFTR in human intestinal epithelial cells
Favorite
(217) Benefits of Gastrostomy Tube Placement on Clinical Outcomes in Children with Cystic Fibrosis
Favorite
(218) Body Composition Changes of Paediatric Patients aged 6-18 years on Kaftrio using Bioelectrical Impedance (BIA)
Favorite
(219) Changes in BMI to FEV1 correlation post-elexacaftor/tezacaftor/ivacaftor therapy
Favorite
(220) Changes in Liver Function Tests and Liver Stiffness Measurements over 12 months in Cystic Fibrosis Patients commenced on Elexacaftor/Tezacaftor/Ivacaftor at a Large Adult Center
Favorite
(221) COVID-19; Evolution of nutritional status in children with cystic fibrosis at the Federico Gomez Children's Hospital in Mexico.
Favorite
(222) Discovery of Novel Genetic Variants in Severe CF Liver Disease as Determined by Whole Genome Sequencing
Favorite
(223) Divergent liver enzyme tests across the first year of Elexacaftor/Tezacaftor/Ivacaftor therapy
Favorite
(224) Elexacaftor/Tezacaftor/Ivacaftor alters Gastrointestinal Symptoms and Inflammation: Report of PROMISE Peds GI
Favorite
(225) Essential Fatty Acid and Lipoprotein Status in Pediatric CF: Impact of CFTR Modulators
Favorite
(226) Evaluation of the Use of Appetite Stimulants in Pediatric Patients with Cystic Fibrosis
Favorite
(227) Fat-soluble Vitamin Status in Patients with Pancreatic Sufficient Cystic Fibrosis
Favorite
(228) Hold the Mayo on the "Trikafta" Special! A single center experience.
Favorite
(229) Impact of cystic fibrosis transmembrane conductance regulator(CFTR) modulator therapy on nutritional status, hepatic steatosis, and dyslipidemia
Favorite
(230) Improving the number of completed colonoscopies among eligible adults with cystic fibrosis
Favorite
(231) Improving vitamin adherence for cystic fibrosis patients through video-observed therapy
Favorite
(232) Increases in Weight-for-Age is Associated with Vegetable Intake in Young Children with Cystic Fibrosis Treated with Lumacaftor/Ivacaftor for 24 Weeks
Favorite
(233) MRI metrics in CF before and after elexacaftor / tezacaftor / ivacaftor - the GIFT-CF3 Study
Favorite
(234) Population-Based Point Prevalence of Cystic Fibrosis Liver Disease Amongst Utah Children
Favorite
(235) Prevalence of Colorectal Neoplasia Among Adults with Cystic Fibrosis: A Single Center Experience
Favorite
(236) Screening for celiac disease in cystic fibrosis patients
Favorite
(237) The Impact of Ethnicity and Social Determinants of Health on Weight Gain in Adults with Cystic Fibrosis After 12 Months of Treatment with Elexacaftor-Tezacaftor-Ivacaftor
Favorite
(238) Utilization of a Speech Language Pathologist to Provide Feeding Therapy in a Pediatric Multidisciplinary CF Clinic
Favorite
(239) Weight gain in patients with CF on triple combination modulator
Favorite
